The CPIC Guidelines for potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for RYR1 and CACNA1S, and the CPIC website.
Potent volatile anesthetic agents are used for inducing general anesthesia. Malignant hyperthermia susceptibility can lead to life-threatening reactions to these agents or the depolarizing muscle relaxant succinylcholine.
The CPIC guideline and supplement summarize evidence from the literature for 48 RYR1 and 2 CACNA1S variants identified by the European Malignant Hyperthermia Group as 'diagnostic mutations'.
For further details see the guidelines and supplemental materials on CPIC, or the PharmGKB guideline annotation on the pages for RYR1 and CACNA1S.